Page 5,757«..1020..5,7565,7575,7585,759..5,7705,780..»

Flu season, cold medicine and confusing labels

Posted: Published on February 5th, 2013

FRESNO, Calif. (KFSN) -- Choosing medicine for a cold, flu, and other aches and pains can be overwhelming. Why is the drug aisle so confusing? Dr. Marvin Lipman, Consumer Reports Medical Adviser said, "The problem is labels like extra strength, maximum strength, or ultra-strength really have no standard definition." Take Ultra-Strength Tums. It has 100 percent more of its active ingredient than the regular version. But Gas-X Ultra-Strength has 125 percent more of its active ingredient. "The point is you really have to read the label in order to know how much you're taking," Lipman said. Claims like "all day" and "long acting" are tricky, too. All-day Aleve lasts up to 12 hours. But this all-day medicine lasts 24 hours. With drugs that promise to relieve multiple symptoms, like a cold, flu, and sore throat, you could end up taking something you don't need. "Drugs that treat multiple symptoms often have more than one ingredient, sometimes many," lipman said. So if you take another medicine that contains one of those ingredients, you might wind up taking too much. Consumer reports says best is choosing a single ingredient drug whenever you can, like ibuprofen for aches and pains or acetaminophen for … Continue reading →

Posted in Medicine | Comments Off on Flu season, cold medicine and confusing labels

JoVE expands scientific video publication into chemistry

Posted: Published on February 5th, 2013

Public release date: 4-Feb-2013 [ | E-mail | Share ] Contact: Neal Moawed press@jove.com 617-245-0137 The Journal of Visualized Experiments February 4, 2013 Cambridge, MA: On Monday, February 4, 2013, JoVE (Journal of Visualized Experiments) will launch the first scholarly scientific video publication for chemistry. Following its successful introduction of video publications for the biological and physical sciences, JoVE received numerous requests for a chemistry counterpart. In response, the journal is launching a new section, JoVE Chemistry, dedicated to visualized publication of experiments across different areas of chemistry research including organic chemistry, chemical biology, electrochemistry, and polymer chemistry, among others. "Similar to research in biology and physics, experimental research in chemistry suffers from a lack of reproducibility that can be solved by visualized publication. Therefore, it is natural to expand JoVE's novel publication approach to chemistry as well", says Moshe Pritsker, the CEO and co-founder of JoVE. The debut article in JoVE Chemistry features a novel experimental approach to investigate antifreeze proteins using a device known as the nanoliter osmometer. This video article was filmed at the laboratory of Dr. Ido Braslavsky at the Hebrew University of Jerusalem in Israel. Explaining the function of antifreeze proteins, Dr. Braslavsky says: "When … Continue reading →

Posted in Chemistry | Comments Off on JoVE expands scientific video publication into chemistry

Pediatric Cardiology by Shutikarn Wanichpoonphol, MD, Child Health Center at BHP – Video

Posted: Published on February 5th, 2013

Pediatric Cardiology by Shutikarn Wanichpoonphol, MD, Child Health Center at BHP Pediatric Cardiology by Shutikarn Wanichpoonphol, MD, Child Health Center at Bangkok Hospital Pattaya For more information or Medical Consultation Tel: +6638 259999 (Overseas) or Contact Center 1719 (Pattaya, Thailand) Email: inquiry@bph.co.th By: BangkokHospital Pattaya … Continue reading →

Posted in Cardiology | Comments Off on Pediatric Cardiology by Shutikarn Wanichpoonphol, MD, Child Health Center at BHP – Video

TVAX Biomedical to Present at 15th Annual BIO CEO & Investor Conference

Posted: Published on February 5th, 2013

LENEXA, KS--(Marketwire - Feb 4, 2013) - TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for the treatment of cancer, today announced that the company will present at the 15th Annual BIO CEO & Investor Conference.The conference will take place February 11-12, 2013 at the Waldorf Astoria Hotel in New York City.Phil Haworth, Ph.D., chief executive officer of TVAX, will present a corporate update on Monday, February 11, 2013 at 1:45 p.m. (Eastern) in the Park South presentation room. Dr. Haworth will also be available for one-on-one meetings with investors during the conference.If you are interested in meeting with Dr. Haworth, please contact Stephanie Diaz of Vida Strategic Partners at 415-675-7401 or sdiaz@vidasp.com. About TVAX Biomedical TVAX Biomedical is a clinical stage development company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company's proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. TVAX Immunotherapy is a unique personalized "killer" T cell treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. A key … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on TVAX Biomedical to Present at 15th Annual BIO CEO & Investor Conference

Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11

Posted: Published on February 5th, 2013

MADISON, Wis., Feb.4, 2013 /PRNewswire/ --Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the 15th Annual BIO CEO & Investor Conference on Monday, February 11, 2013. Mr. Palmin is scheduled to present at 2pm ET in the Duke of Windsor Suite on the 4th floor. The event will be held February 11-12 at The Waldorf Astoria in New York City. A live webcast of the Novelos presentation may be accessed via http://www.novelos.com The webcast will be archived for 90 days following the presentation. The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Information about the conference is available at http://www.bio.org/events/conferences/bio-ceo-investor-conference About Novelos Therapeutics, Inc.We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11

Canada Approves Seattle Genetics' Adcetris

Posted: Published on February 5th, 2013

Seattle Genetics Inc. (SGEN) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). Adcetris has been approved under Health Canada's Notice of Compliance with conditions (NOC/c) for the treatment of patients with Hodgkins lymphoma (HL) after failure of autologous stem cell transplant (:ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris was also approved for the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen. For similar indications, Adcetris was approved by the US Food and Drug Administration (:FDA) in Aug 2011 and in the EU in Oct 2012. The NOC/c requires Seattle Genetics to conduct clinical trials to confirm the anticipated clinical benefit of Adcetris. Seattle Genetics is currently enrolling patients for two confirmatory phase III studies evaluating the drug for the front-line treatment of HL and mature T-cell lymphoma (:MTCL), including sALCL. Meanwhile, in Jan 2013, a global phase III study (ECHELON-2) was initiated on Adcetris. In this study, Adcetris plus chemotherapy will be evaluated for the front-line treatment of CD30-positive MTCL including patients with sALCL and other types of peripheral T-cell lymphomas. Our … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Canada Approves Seattle Genetics' Adcetris

Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests

Posted: Published on February 5th, 2013

Public release date: 4-Feb-2013 [ | E-mail | Share ] Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center STANFORD, Calif. - An antibody that binds to a molecule on the surface of a rare but deadly tumor of the gastrointestinal tract inhibits the growth of the cancer cells in mice, according to researchers at the Stanford University School of Medicine. The effect remains even when the cancer cells have become resistant to other treatments, and the findings may one day provide a glimmer of hope for people with the cancer, known as gastrointestinal stromal tumor, or GIST. The scientists hope to move into human clinical trials of the antibody within two years. The antibody's target is a receptor called KIT, which is often mutated in patients with the cancer. When mutated, KIT sends a continuous stream of messages into the cell urging it to grow uncontrollably. The Stanford researchers found that the antibody reduces the amount of KIT on the surface of the cancer cells and stimulates immune cells called macrophages to kill the rogue cells. Currently, people with GIST are often treated first with surgery and then with the drug imatinib, marketed as Gleevec - a small molecule … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests

Cutting-Edge Medical And Stem Cell Technology Available In The Philippines But DoH cites concerns

Posted: Published on February 5th, 2013

Department of Health Undersecretary Dr. Teodoro Herbosa recently urged the public seeking treatment using stem cell technology to only undergo procedure initiated by reputable hospitals in the country. The highly advanced procedure of using stem cell technology has recently gained popularity due to success claims of scientists here and abroad. However, due to the increasing demand for this technology, USEC Herbosa expressed concern that some individuals needing treatment might end-up in bogus clinics usually offering lower fees. "Just to ensure safety, it will be best for patients to seek treatment only among reputable hospitals," Usec. Herbosa stated in an interview. Incidentally, a leading global Filipino scientist in the field of genetics and microbiology stated that the Philippines is now one of the leading countries in the world, even a step ahead of Germany, in the field of health science. Presidential Awardee Dr. Samuel D. Bernal, a Filipino-American regenerative medicine expert, medical oncologist, molecular biologist, chemist and a lawyer, calls on Filipinos here and abroad to patronize the technology we have here in the country. "Very few know about it, but we can already actually culture or clone a human heart in the Philippines," claimed by Dr. Bernal in a recent … Continue reading →

Comments Off on Cutting-Edge Medical And Stem Cell Technology Available In The Philippines But DoH cites concerns

First Patient Begins Treatment in BrainStorm’s Phase IIa Trial for ALS

Posted: Published on February 5th, 2013

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Companys Phase IIa dose-escalating clinical trial for ALS. The trial, which will evaluate the safety and preliminary efficacy of BrainStorms NurOwn stem cell therapy candidate, is being conducted at the Hadassah Medical Center in Jerusalem. In the Phase IIa trial, three groups of four patients will receive combined intramuscular and intrathecal administration of NurOwn cells, in increasing doses. The first cohort of four patients is expected to complete treatment by the end of April 2013. The trial participants will be monitored for three to six months following transplantation. We are excited to be treating the first patient in this trial, which will build on the excellent safety profile and encouraging positive results from our Phase I/II study, commented Alon Natanson, BrainStorms CEO. This trial will provide valuable data not only on the safety of NurOwn in ALS patients, but also on the ability of different dosing levels to provide clinical benefit, added Prof. Dani Offen, the Companys Chief Scientific Advisor. Israels Ministry of Health recently approved BrainStorms acceleration … Continue reading →

Comments Off on First Patient Begins Treatment in BrainStorm’s Phase IIa Trial for ALS

International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease

Posted: Published on February 5th, 2013

CARLSBAD, CA--(Marketwire - Feb 4, 2013) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company, today announced positive 12-week results from its pre-clinical in vivo Parkinson's disease study. The primary goal of this behavioral study was to demonstrate the therapeutic benefits of neuronal cells derived from human parthenogenetic stem cell (hpSC) line in a rat model of Parkinson's disease (PD). Parkinson's disease is a common neurodegenerative disorder caused by a progressive degeneration of dopamine-producing neurons resulting in gradual dysfunction of the motor system and can eventually lead to death. Pharmacological treatments are useful in the relatively early stage of the disease, but the continuous use of pro-dopaminergic medication eventually becomes ineffective and can cause some of the motor symptoms to worsen. Our proprietary technology is based on a homogeneous population of neuronal cells (NCs) derived from homozygous hpSCs through a scalable and efficient method, developed by ISCO's R&D team. These parthenogenetically-derived NCs are cryopreservable and can become neurons once they are implanted into the brain. As such, they hold significant therapeutic potential not only because they can differentiate into dopamine-producing neurons, but also because these cells deliver trophic factors that … Continue reading →

Comments Off on International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease

Page 5,757«..1020..5,7565,7575,7585,759..5,7705,780..»